Biocon Biologics
Biocon Biologics is a Bangalore-based, fully integrated biosimilars company developing and commercializing affordable biosimilar therapies for diabetes, oncology, and immunology, serving 6+ million patients annually across 100+ countries with first-to-market FDA interchangeable designations.
- Company typePrivate
- Founded1978
- HeadquartersBangalore, India
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Biocon Biologics does
Biocon Biologics is a fully integrated, pure-play biosimilars company headquartered in Bangalore, India, and now a wholly owned subsidiary of Biocon Limited following full integration completed in 2026. The company develops, manufactures, and commercializes high-quality, affordable biosimilars across three primary therapeutic verticals: diabetes care (insulin glargine, insulin aspart, semaglutide biosimilar Glupryze, and liraglutide generic gSaxenda), oncology (trastuzumab, bevacizumab, denosumab under brands Bosaya, Aukelso, Vevzuo, and Evfraxy, plus ustekinumab as Yesintek), and immunology (adalimumab as Hulio). It serves 6+ million patients annually across 100+ countries, with 10 biosimilars commercialized globally and 20 in its broader pipeline.
The company's core technology rests on a proprietary Pichia pastoris expression platform for recombinant proteins (pioneered commercially with human insulin in 2004), mammalian cell culture capabilities, and integrated fill-finish manufacturing across facilities in India and Malaysia (including Asia's largest insulin plant at RM1.63 billion in Johor). It holds multiple first-to-market regulatory milestones, including the first US FDA interchangeable biosimilar designations for bGlargine (2021), bAflibercept (2024), and bAspart (2025), and the first FDA approvals for biosimilar trastuzumab and pegfilgrastim.
Revenue is generated through a hybrid commercial model: direct enterprise field sales and specialty pharmacy distribution in advanced regulated markets (US, EU, Canada, Japan, Australia), combined with tender-based and distributor-led sales in emerging markets. The business is anchored by biosimilars (~60% of FY26 revenue), with secondary contributions from generics (~18-24%), CRDMO services through Syngene International, and insulin manufacturing partnerships (notably Civica for the US CalRx program at $11/vial). FY26 consolidated operating revenue was ₹16,927 crore, with biosimilars growing 16% year-over-year and EBITDA up 40% on a like-to-like basis.
Biocon Biologics firmographics
Firmographics- Name
- Biocon Biologics
- Legal name
- Biocon Biologics Limited
- Website
- https://bioconbiologics.com
- Company type
- Private
- Founded year
- 1978
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Biocon Biologics is a Bangalore-based, fully integrated biosimilars company developing and commercializing affordable biosimilar therapies for diabetes, oncology, and immunology, serving 6+ million patients annually across 100+ countries with first-to-market FDA interchangeable designations.
- Ownership category
- akta.pro rank
Biocon Biologics industry classification
Industry- Product category
- Biosimilar Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biosimilar Manufacturing & Fill-Finish (drug substance/drug product, device integration) (HLAAAHAK)
- akta.pro secondary industries
- Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution) (HLAAAHAL), Oncology Biosimilars (HLAAAHAG), Biosimilar Development & Clinical/Regulatory Services (comparability, trials, pharmacovigilance) (HLAAAHAJ), Biologic API/Drug Substance Manufacturing Services (HLAAAKAA), Biologics & Biosimilars Distributors (HLAIAJAH)
Keywords
Where Biocon Biologics is headquartered
LocationHeadquarters
- HQ city
- Bangalore
- HQ country
- India
- HQ region
- Asia
Offices5 records
Markets served
Biocon Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Biosimilars: Sale of biosimilar products globally through direct commercialization in advanced markets and partnerships in emerging markets. Includes insulins, monoclonal antibodies, and oncology biosimilars. Contributed approximately 60% of total revenue in FY26.
- Generics: Sale of generic pharmaceutical products including complex generics, oral solid dose, and injectable formulations. Contributed approximately 18-24% of revenue with Q4FY26 revenue of ₹847 crore.
- CRDMO Services: Contract research and manufacturing services through Syngene International, providing integrated discovery, development, and manufacturing services to global pharma clients.
- Insulin Manufacturing & Supply: Manufacturing and supply of insulin products to partners like Civica for US market commercialization under CalRx program and other global insulin supply agreements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | California CalRx insulin program pricing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels4 records
Biocon Biologics product offering
Product offeringCore offering
Biocon Biologics is a fully integrated biosimilars company that develops, manufactures, and commercializes affordable biosimilar versions of biologic drugs including insulins, monoclonal antibodies (oncology and immunology), and conjugated recombinant proteins. It sells these products directly in advanced regulated markets and through partnerships in emerging markets, supplying healthcare systems across 100+ countries.
Product overview
Biocon Biologics is a fully integrated biosimilars company offering a portfolio of 20 biosimilars with 10 commercialized in global markets across the US, EU, Australia, Canada, Japan, and over 100 countries. The portfolio spans insulins (Insulin Glargine, Insulin Aspart), monoclonal antibodies (Adalimumab/Hulio, Ustekinumab/Yesintek, Denosumab/Bosaya, Aukelso, Vevzuo, Evfraxy), and conjugated recombinant proteins. Key products include generic Micafungin for antifungal treatment and gSaxenda (Liraglutide generic) for obesity. The company operates across advanced markets (US, EU, Canada, Japan) and emerging markets, with manufacturing facilities in India and Malaysia.
Differentiator
Problem solved
Functional benefit
Brands
- Bosaya: Denosumab biosimilar for treating osteoporosis and bone complications from cancer, launched in the US in April 2026
- Aukelso
- Yesintek
- Hulio
- Vevzuo
- Evfraxy
- Glupryze
- gSaxenda
Products and services
- Bosaya (Denosumab Biosimilar) A denosumab biosimilar for treating osteoporosis and bone complications from cancer, with interchangeable designation from US FDA. Distributed through specialty pharmacies in the US.
- Aukelso (Denosumab Biosimilar) A denosumab biosimilar for treating osteoporosis and bone complications from cancer, with interchangeable designation from US FDA. Distributed through specialty pharmacies in the US.
- Yesintek / Yesintek I.V. (Ustekinumab Biosimilar) Biosimilar to Stelara approved by Health Canada for treating autoimmune conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Yesintek captured nearly 20% US market share for ustekinumab biosimilar.
- Hulio (Adalimumab Biosimilar) Adalimumab biosimilar for treating autoimmune conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Biocon acquired full global rights in December 2025.
- Insulin Glargine (Private Label) Long-acting insulin glargine manufactured by Biocon and distributed by Civica under private label in the US market, interchangeable with Lantus. Part of California CalRx program offering 40-70% discount to market prices.
- gSaxenda (Liraglutide Generic) Generic version of GLP-1 weight management drug Liraglutide (Saxenda), approved by USFDA for obesity treatment in the US market.
- Micafungin for Injection Antifungal injection approved by Health Canada for treating Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses, esophageal candidiasis, and prophylaxis of Candida infections in adults and children four months and older.
- Vevzuo (Denosumab Biosimilar) Denosumab biosimilar targeting skeletal-related events in cancer patients, launched in Europe from December 2025 following Amgen settlement.
- Evfraxy (Denosumab Biosimilar) Denosumab biosimilar for treating osteoporosis, launched in Europe from December 2025 following Amgen settlement.
Quantifiable outcome
- 6+ million patients benefit annually from biosimilar therapies
- +3 more outcomes
Companies that use Biocon Biologics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Biocon Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Biocon Biologics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- BahiaFarma and BionovisminorMoU signed at Ficci India-Brazil Business Forum for developing pertuzumab biosimilar for HER-2 metastatic breast cancer treatment in Brazil, in presence of Brazilian President Lula da Silva.
- Fujifilm Kyowa Kirin Biologics (FKB)coreExpanded deal to acquire full global rights for adalimumab biosimilar (Hulio), replacing previous partnership with complete control over manufacturing, commercialization, and future development. FKB continues supporting development with technology transfer.
- AmgencoreSettlement agreement to commercialize denosumab biosimilars (Vevzuo, Evfraxy) in Europe and international markets. Both biosimilars received European Commission approval in July 2025. Agreement builds on prior US settlement.
- CivicacoreExpanded partnership for private-label insulin glargine manufacturing and supply in US. Civica markets and distributes insulin under CalRx program at $11 per vial. Biocon manufactures insulin at Malaysia facility for US commercialization.
- Janssen Biotech Inc.coreBiosimilar commercialization agreement for unspecified biosimilar products. Deal part of Biocon's strategy to expand biosimilar portfolio globally.
Scale indicators10 records
Recent moves6 records
Expansion highlights7 records
Biocon Biologics competitors and assessment
Company assessmentDirect peers
- Celltrion: South Korean biosimilars company with a comparable fully integrated biosimilars portfolio (Remsima, Truxima, Herzuma, etc.) targeting the same reference biologics in oncology and immunology. Closest direct competitor in scale and commercialization model.
- Samsung Bioepis: Joint venture between Samsung Biologics and Biogen developing biosimilars in oncology, immunology, and ophthalmology. Direct competitor in interchangeable biosimilar filings and US market share capture.
- Alvotech: Iceland-based biosimilar developer with interchangeable biosimilar programs in ophthalmology (aflibercept) and immunology. Competes head-to-head in US interchangeable biosimilar space.
Broad incumbents
- Sandoz (Novartis): Global biosimilars and generics leader with a broad biosimilars portfolio (Hyrimoz, Omnitrope, Erelzi) and full pharmaceutical infrastructure. Overlaps with Biocon across most biosimilar molecules but operates at much larger scale.
- Amgen: Originator of Prolia/Xgeva (denosumab), Stelara (ustekinumab), and many other reference biologics that Biocon biosimilars compete against. Also a partner via the Amgen settlement for EU denosumab launches.
- Viatris (Mylan): Former commercial partner from which Biocon acquired the global biosimilars business for $3.3B. Continues as a residual minority stakeholder and broader pharmaceutical peer in biosimilars/commercialization.
Emerging players
- mAbxience: Insud Pharma's biosimilars arm with oncology-focused biosimilars (rituximab, trastuzumab, bevacizumab) competing in EU and emerging markets. Comparable emerging-market commercial model and biosimilar pipeline scope.
- Fujifilm Kyowa Kirin Biologics (FKB): Former adalimumab biosimilar (Hulio) partner that transferred full global rights to Biocon in December 2025. Overlapping biosimilar development capabilities and pipeline.
Regional players
- Intas Pharmaceuticals: Indian biopharmaceutical company with biosimilars (Accofil, Neukine) and a global specialty injectables footprint. Comparable in Indian-origin manufacturing scale and emerging market commercialization.
Others
- Syngene International: Biocon Group's listed CRDMO arm providing contract biomanufacturing and research services. Sister company and ecosystem enabler, not a direct competitor but a key adjacent business within the Biocon Group.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Biocon Biologics social profiles
Digital presenceBiocon Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biocon Biologics leadership team
Management profileNumber of profiles
Profiles3 records
Biocon Biologics subsidiaries and ownership
Company hierarchySubsidiaries4 records
Biocon Biologics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biocon Biologics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biocon Biologics
What does Biocon Biologics do?
Biocon Biologics is a fully integrated biosimilars company that develops, manufactures, and commercializes affordable biosimilar versions of biologic drugs including insulins, monoclonal antibodies (oncology and immunology), and conjugated recombinant proteins. It sells these products directly in advanced regulated markets and through partnerships in emerging markets, supplying healthcare systems across 100+ countries.
Is Biocon Biologics a public or private company?
Biocon Biologics is a private company. It is classified as corporate owned and is currently operating.
When was Biocon Biologics founded?
Biocon Biologics was founded in 1978. It employs 5,001 to 10,000 people.
Where is Biocon Biologics based?
Biocon Biologics is headquartered in Bangalore, India, in the Asia region.
How does Biocon Biologics make money?
Four revenue lines are on record. Biosimilars are the primary driver. The others are generics, CRDMO Services and insulin Manufacturing & Supply.
Who are Biocon Biologics's main competitors?
Direct peers on record are Celltrion, Samsung Bioepis and Alvotech. Broad incumbents are Sandoz (Novartis), Amgen and Viatris (Mylan). Emerging players are mAbxience and Fujifilm Kyowa Kirin Biologics (FKB). Intas Pharmaceuticals is listed as a regional player. Syngene International is listed as an others.
Does Biocon Biologics have an API?
No public API is recorded for Biocon Biologics.
What industry is Biocon Biologics in?
Biocon Biologics's product category is Biosimilar Pharmaceuticals. Its primary akta.pro industry code is HLAAAHAK, Biosimilar Manufacturing & Fill-Finish (drug substance/drug product, device integration), with a secondary code of HLAAAHAL, Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution). Its NAICS code is 325414 and its SIC code is 2836.